SOAN FIRST TITAN CORP

AngioSoma Committed to Expanding Cosmeceutical Future

AngioSoma Committed to Expanding Cosmeceutical Future

New Industry Data and Product Roadmap Align for Optimistic Outlook

HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research and development company, reaffirms its position and future goals within the cosmeceutical space based on new industry data.  

The global cosmeceuticals market was valued at USD 46.93 billion in 2017, and is expected to reach a value of USD 80.36 billion by 2023 at a CAGR of 9.38%, over the forecast period (2018—2023).  With an aging population and life expectancy rising, the demand for natural youth-sustaining cosmeceutical products will be spiking for the foreseeable future.  Plant stem cell based and antioxidant rich products will usher in a new generation of cosmeceutical products that AngioSoma plans on developing in the near term.  

“We are committed to expanding our reach in this industry,” said Alex Blankenship, President of AngioSoma. “As people value natural alternatives more, our products will become a more attractive choice in the future.  Given our already successful products and the new cosmeceutical products launching in the near future, AngioSoma is poised to capture market share going forward.”

You can view and purchase products on Amazon.com:  

Also, products can be found on our ecommerce site: 

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaCeuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Contact

AngioSoma, Inc.
Alex Blankenship
EN
08/11/2018

Underlying

SOANFIRST TITAN CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIRST TITAN CORP

 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

AngioSoma and its Subsidiary SomaCeuticals Announce Amended and Restat...

AngioSoma and its Subsidiary SomaCeuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent Houston, TX, Feb. 11, 2021 (GLOBE NEWSWIRE) --  -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”), through its wholly-owned subsidiary, SomaCeuticals, Inc., is pleased to announce that the Exclusive Global Multiple Sclerosis License Agreement dated August 23, 2020 has been amended and restated as of February 4, 2021 to give both parties a stronger and more robust platform to move synergistically forward to market and license Patent 10,619,592 issued to...

February 11, 2021 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis

SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis Houston, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company’s subsidiary, SomaCeuticals, Inc., has defined its mission to bring its enhanced treatment for Multiple Sclerosis to patients worldwide.   After an intensive search, the Company has identified a well-known firm with a capable team that may be engaged to help with regulatory clearance of the treatment for worldwide treatment of patients. The treatment is encouraged by t...

December 8, 2020 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

SomaCeuticals Acquires License for Treatment of Multiple Sclerosis

SomaCeuticals Acquires License for Treatment of Multiple Sclerosis Houston, TX, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the company’s subsidiary, SomaCeuticals, Inc., has executed a licensing agreement with 7 to Stand, Inc. (a Delaware corporation) for the exclusive global rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis (MS). Multiple Sclerosis (MS) is a chronic disease in which the immune system ...

August 24, 2020 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

SomaCeuticals Elects New President

SomaCeuticals Elects New President Houston, TX, Aug. 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the company’s subsidiary, SomaCeuticals, Inc., has elected James C. Katzaroff as President to serve until his successor is elected and qualified. Mr. Katzaroff is in discussions with the holder of a patented treatment for Multiple Sclerosis with the intent to negotiate an exclusive perpetual license. Mr. Katzaroff is the founder of Advanced Medical Isotope Corp. (now known as Radiogel) and was the Chairm...

August 17, 2020 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

AngioSoma Focusing on Development of Coating for Metal Stents

AngioSoma Focusing on Development of Coating for Metal Stents Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.  A stent is an expandable “scaffold-like” device, usually constructed of a metallic material, that is inserted into an artery to expand the inside passage and improve blood flow for prevention of vascular restenosis and treatment of complex vascular and coronary disease.  A bifurcated ver...

May 27, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch